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Abstract
Background: We sought to evaluate perinatal outcomes by race/ethnicity among women with gestational di-
abetes mellitus (GDM).
Methods: We conducted a 14-year retrospective cohort study of women with GDM. Selected perinatal outcomes
were examined. Unadjusted and adjusted prevalence ratios (PR, aPR) of perinatal outcomes, comparing His-
panic and African American women with Caucasian women, were calculated.
Results: Hispanics comprised 54% of the 1018 woman cohort. Half received medical management of GDM
(52%), more than African Americans (45%) or Caucasians (39%)( p < 0.05). Compared with Caucasians, Hispanics
had fewer deliveries < 37 weeks (aPR 0.58, 95% confidence interval [CI] 0.42-0.81), less gestational hypertension
(aPR 0.43, 95% CI 0.22-0.83), larger median birth weight infants (3453 g vs 3291 g, p < 0.05), and greater risk of
shoulder dystocia (aPR 3.52, 95% CI 1.30-9.50). Hispanic women had fewer adverse outcomes overall compared
with Caucasian or African American women.
Conclusions: We report differences between Hispanic and Caucasian women with GDM. Treatment to achieve
glycemic control and reduce adverse outcomes may differ by race/ethnicity.
Introduction
Gestational diabetes mellitus (GDM) complicates4%–7% of all pregnancies.1 Untreated or poorly con-
trolled GDM is associated with adverse perinatal outcomes,
including large for gestational age (LGA), shoulder dystocia,
cesarean delivery, and hypertensive disorders of pregnan-
cy.2,3 Strict glycemic control through diet or medical treat-
ment lowers the risks of these adverse outcomes.4 Prevalence
of GDM varies by race/ethnicity. Hispanic women in the
United States have a higher prevalence of GDM compared
with Caucasian or African American women.5–7 In a large
North Carolina cohort, Hispanic women were 50% more
likely to have GDM compared with Caucasian or African
American women.8
Differences in risk of adverse perinatal outcomes by eth-
nicity, however, are less clear. Among those without GDM,
Hispanic women are less likely to deliver low birth weight
(LBW) infants, experience lower neonatal mortality,9,10 and
have had a lower reported prevalence of preeclampsia com-
pared with Caucasians and African Americans.8 Nonpregnant
Hispanics are less likely to develop hypertension at a given
body mass index (BMI) compared with non-Hispanic white or
blacks women and East Asians.11 Ethnic differences in insulin
resistance, as well as protective social factors, may contribute
to these unexpected better health outcomes among Hispanics
despite their overall socioeconomic disadvantage, which typi-
cally has been associated with poorer health outcomes.12
Some data specific to women with GDM have suggested
that adverse outcome risk may also vary by race/ethnicity.13–15
Findings conflict, however, and recent data suggest the
magnitude of racial/ethnic differences is small, particularly
when individual, more narrowly defined racial/ethnic
groups are evaluated.16,17 The association of race/ethnicity
with complications of GDM and the role GDM treatment may
play thus remain unclear.
Hispanics are the largest ethnic minority in the United
States and are projected to be nearly 30% of the population by
2050.18 With an overall growing prevalence of GDM and a
disproportionate burden among Hispanic women, under-
standing racial/ethnic differences in GDM treatment and
perinatal outcomes is an important step toward potentially
tailoring treatment to improve perinatal health. In this retro-
spective 14-year cohort of women with GDM, we, therefore,
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measured the association between race/ethnicity and GDM
management and adverse outcomes among Hispanic, African
American, and Caucasian women with GDM.
Materials and Methods
Study cohort
We conducted a retrospective cohort study of all women
diagnosed with GDM who delivered at University of North
Carolina (UNC) Womens’ Hospital, Chapel Hill, NC, between
April 1, 1996, and May 31, 2010. Women were excluded if they
delivered prior to 24 weeks’ gestation, had pregestational
diabetes, or did not have a documented GDM screening
and diagnostic test result. All other women who delivered at
UNC Womens’ Hospital during the study period were in-
cluded in the study cohort. Neonatal data for the firstborn
were used in multiple gestations. UNC Institutional Review
Board approval was obtained for this study.
Gestational diabetes diagnosis
At our institution, we perform universal screening for GDM
between 24 and 28 weeks’ gestation with a 50-g, 1-hour oral
glucose load. Women who screened positive with plasma
glucose values ‡ 140 mg/dL during the study period under-
went diagnostic testing with a 100-g, 3-hour oral glucose tol-
erance test (OGTT). Women diagnosed with GDM based solely
on the results of their 1-hour oral glucose load (plasma glucose
‡ 200 mg/dL or at the discretion of provider) were not included
in the analysis. During the study period, National Diabetes
Data Group (NDDG) diagnostic criteria were followed (fast-
ing, ‡ 105 mg/dL; 1 hour, ‡ 190 mg/dL; 2 hour, ‡ 165 mg/dL;
3 hour, ‡ 145 mg/dL), and women with two or more OGTT
values above thresholds were diagnosed with GDM.19
Women were cared for by attending physicians and fellows
and residents under attending supervision, using the following
protocol: after diagnosis, women received nutritional counsel-
ing with instruction for glucose self-monitoring. Diet recom-
mendations initially follow the American Dietetic Association
regarding carbohydrate intake, based on body mass index mg/
kg2 (BMI), and were tailored to the individual patient as indi-
cated.20 Capillary blood glucose goals were fasting < 105 mg/
dL and 1-hour postprandial < 140 mg/dL or 2-hour postpran-
dial < 130 mg/dL. Patient report of glucose self-monitoring was
reviewed at each clinic visit, and adequate glycemic control was
defined as ‡ 50% of blood glucose levels at goal levels. Medical
therapy was initiated (subcutaneous insulin, also oral glyburide
as of 2004) if these goal levels were not achieved with diet alone.
Data abstraction
We abstracted maternal demographic data and pregnancy
diagnoses from the UNC Perinatal Database (PD) to create
our research database. Clinical providers prospectively record
perinatal data from all deliveries at UNC, and trained ab-
stractors enter information into and maintain the PD. Women
who did not deliver at UNC, regardless of any care received at
this institution, were not included in the PD. Before analysis,
outliers and clinically implausible values were identified by
exploratory analysis and corrected by review of original pa-
per charts and electronic medical records (EMRs). A random
sample of 200 records was cross-referenced with original pa-
per charts and EMRs to ascertain accuracy of key variables.
Race/ethnicity was recorded during prenatal care as Cau-
casian, African American, Hispanic, Asian, or other/not re-
ported. These data were abstracted from the UNC PD for
analysis. As the Hispanic population in North Carolina was
63% of Mexican origin and 37% of non-Mexican origin in 2009
and has consistently increased throughout our study period,
self-reported race/ethnicity reflects the nonhomogeneous
nature of this group.21
Perinatal outcomes
We assessed perinatal outcomes found to improve with
treatment of mild GDM in randomized controlled trials.2,4,22
Birth weight in grams and gestational age at delivery were
abstracted as continuous variables and further considered as
categorical variables. Other abstracted categorical variables
included mode of delivery (spontaneous vaginal, operative
vaginal, cesarean), 3rd or 4th degree perineal laceration,
preeclampsia, gestational hypertension, shoulder dystocia,
neonatal intensive care unit (NICU) admission, and NICU
stay length > 24 hours. We classified GDM management as
diet control if a woman did not receive any medical man-
agement (insulin or glyburide) during pregnancy and as
medical management if the medical record reflected any ad-
ministration of glyburide or insulin during pregnancy.
Statistical analysis
We analyzed maternal demographic variables and preg-
nancy diagnoses among women with GDM by three self-
reported racial/ethnic groups: Caucasian, African American,
and Hispanic. Bivariate analysis included one-way analysis of
variance (ANOVA) and Kruskal-Wallis for continuous vari-
ables and Pearson’s chi-square for categorical variables, with
p < 0.05 statistically significant. Means with standard devia-
tions (SD) and medians with interquartile ranges (IQR) were
reported for continuous variables with normal and non-
normal distributions, respectively.
In multivariate analyses of adverse perinatal outcomes,
African American and Hispanic women were individually
compared with the reference group, Caucasian women. We
compared the prevalence of each dichotomous adverse out-
come, fitting Poisson regression models with robust standard
errors (SE) to account for women with more than one preg-
nancy in our database.23 Variables significant in bivariate
analysis or identified in published literature as clinical risk
factors for the outcome of interest were considered for inclu-
sion in adjusted models. All final Poisson regression models
included 1-hour oral glucose load results as a continuous
variable and tobacco use in pregnancy as a dichotomous
variable. Gestational age at delivery was not included in
models, as adjusting for this intermediate in the causal path-
way between GDM and selected outcomes can produce bi-
ased estimates of direct effects.24 We reported unadjusted and
adjusted prevalence ratios (PR, aPR) with 95% confidence
intervals (CI), and CIs that excluded the null were statistically
significant. Stata 10.0 (StataCorp, College Station, TX) was
used for all analyses.
Results
From April 1, 1996, to May 31, 2010, 33,179 women of any
race/ethnicity were screened for GDM with a 50-g 1-hour oral
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glucose load and met initial study inclusion criteria. Overall
disease prevalence among the 33,179 women screened for
GDM was 3.3 % (1,082 of 33,179). GDM prevalence was
greatest among Hispanic women, 4.9% (552 of 11,201), fol-
lowed by African American women at 2.6% (155 of 5,877).
Caucasian women had the lowest GDM prevalence, 2.2% (311
of 14,412). Figure 1 illustrates our study sample from eligi-
bility through GDM diagnosis; 320 women classified as GDM
and referred for treatment based solely on an elevated
screening test ( ‡ 200 mg/dL or at the discretion of the primary
provider) were not included in further analysis. Compared
with the 1,018 women who comprised our final sample for
analysis, these 320 women not included were less likely to be
Hispanic (44% vs. 54%, p < 0.05), more likely to be African
American (22% vs. 15%, p < 0.05), and equally likely to be
Caucasian (34% vs. 31%, p ‡ 0.05). Compared with screen-
positive women who underwent a 3-hour OGTT result, the
15% who did not have 3-hour OGTT results available (795 of
5,454) were less likely to be Hispanic (37% vs. 45%, p < 0.05)
and more likely to be Caucasian (40% vs. 36%, p < 0.05) or
African American (18% vs. 12%) ( p < 0.001). This 15%, or 795
women, had 1-hour glucose load values of 150 mg/dL (IQR
144–162) compared with median values of 153 mg/dL (IQR
146–165) among women who completed a 3-hour OGTT but
did not meet diagnostic criteria for GDM.
Of the 4,659 women who underwent diagnostic testing,
23% (1,082 of 4,659) were diagnosed with and treated for
GDM by NDDG criteria. After excluding women of Asian and
other or unknown (n = 64), our final sample of 1,018 women
with GDM was 54% Hispanic (552 of 1,018), 31% Caucasian
(311 of 1,018), and 15% African American (155 of 1,018). Fifty-
three percent (543 of 1,018) of the study sample of diagnosed
and treated women achieved goal glucose thresholds with
nutritional counseling and dietary management alone. The
remaining 47% (475 of 1018) were treated with medical
management with either glyburide or insulin. Hispanic wo-
men were more likely to be treated with medical management
than either Caucasian (52% vs. 39%, p < 0.001) or African
American (52% vs. 45%, p = 0.002) women. Maternal demo-
graphic and pregnancy data are shown in Table 1.
As shown in Table 2, in unadjusted bivariate analysis,
Hispanic women delivered infants of greater birth weight and
at greater median gestational ages and had fewer preterm
births < 37 and < 34 weeks compared with Caucasian women.
African American women were more likely to have each of
these measured outcomes ( p < 0.05 for each comparison)
compared with Caucasian women.
Adjusted maternal and infant outcomes are shown in Table
3. Hispanic and African American women were each com-
pared with the reference group, Caucasian women. Adverse
outcomes that were significantly different in unadjusted ana-
lyses remained significant in final adjusted models. Adjusting
for 1-hour oral glucose load results and tobacco use in preg-
nancy did not substantially change the magnitude or precision
of results. Hispanic women had lower likelihood of LBW infant
(aPR 0.54, 95% CI 0.36-0.82) and very low birth weight (VLBW)
infant (aPR 0.20, 95% CI 0.04-1.01) compared with Caucasian
women. Macrosomia risk, however, was 21% greater (aPR 1.21,
95% CI 0.83-1.76) among Hispanic women compared with
Caucasian women. Shoulder dystocia was statistically more
common among Hispanic women compared with Caucasian
women (aPR 3.52, 95% CI 1.30-9.50). Hispanic women were
significantly less likely to deliver preterm < 37 weeks (aPR 0.58,
95% CI 0.42-0.81) and < 34 weeks (aPR 0.51, 95% CI 0.27-0.96),
compared with Caucasian women.
The prevalence of hypertensive disorders of pregnancy was
also considered in multivariate analysis. Hispanic women
were less than half as likely to be diagnosed with gestational
hypertension in both unadjusted and adjusted models (aPR
0.43, 95% CI 0.22-0.83) compared with Caucasian women.
FIG. 1. Flow of gestational
diabetes mellitus (GDM)
cohort, from eligibility
through sample for analysis.
NDDG, National Diabetes
Data Group.
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However, the prevalence of preeclampsia (mild or severe)
was similar between the two racial/ethnic groups in both
adjusted and unadjusted models (Table 3).
NICU admission and length of stay were examined.
Compared with infants of Caucasian women, infants of His-
panic mothers were nearly 30% less likely to be admitted to
the NICU (aPR 0.72, 95% CI 0.59-0.88). Among infants ad-
mitted to the NICU, Hispanic infants were 0.81 times as likely
to be admitted for > 24 hours (aPR 0.81, 95% CI 0.72-0.90) as
Caucasian infants (Table 3).
In contrast to comparisons between Hispanic and Cauca-
sian women, outcomes were similar between African Amer-
ican and Caucasian women for most measured outcomes.
In unadjusted analyses, African American women were not
more likely to experience our measured adverse perinatal
outcomes compared with Caucasian women. In adjusted
models, controlling for 1-hour glucose load results and to-
bacco use in pregnancy, African American women remained
equally likely as Caucasian women to be diagnosed with
other adverse outcomes (Table 3).
Table 2. Perinatal Outcomes Among Women Diagnosed with Gestational Diabetes Mellitus
by 3-Hour Oral Glucose Tolerance Test (n = 1018), by Three Categories of Race/Ethnicity
Median (IQR) or n (%)a
Variable Hispanic (n = 552) Caucasian (n = 311) African American (n = 155)
Birth weight (grams)* 3,453 (3,050–3,812) 3,291 (2,869–3,743) 3,260 (2,850–3,750)
Macrosomia > 4,000 g 90 (16) 37 (12) 15 (10)
Low birth weight < 2,500g* 43 (8) 44 (14) 23 (15)
Very low birth weight < 1,500g* 2 (0.4) 6 (2) 7 (5)
Cesarean (vs. spontaneous vaginal delivery, n = 957) 198 (38) 117 (41) 66 (45)
Operative (vs. spontaneous vaginal delivery, n = 637) 27 (8) 27 (14) 7 (8)
3rd or 4th degree laceration 16 (3) 15 (5) 3 (2)
Gestational age at delivery (weeks)* 39.0 (38.1–39.9) 38.9 (37.3–39.9) 38.7 (37.1–39.6)
Preterm delivery < 37 weeks* 67 (12) 66 (21) 32 (21)
Preterm delivery < 34 weeks* 19 (3) 20 (6) 13 (8)
Preeclampsia 36 (7) 24 (8) 19 (12)
Gestational hypertension* 16 (3) 23 (7) 10 (6)
Shoulder dystocia* 28 (5) 5 (2) 7 (5)
NICU admission* 160 (29) 123 (40) 51 (33)
> 24-hour NICU stay (if admitted)* 118 (74) 105 (89) 44 (90)
aNumbers may not add up to 100 because of rounding.
*p < 0.05, significant differences among groups by one-way ANOVA, Kruskal-Wallis tests.
NICU, neonatal intensive care unit; IQR, interquartile range; no, number.
Table 1. Characteristics by Race/Ethnicity
Mean (SD), median (IQR), or no (%)a
Hispanic (n = 552) Caucasian (n = 311) African American (n = 155)
Maternal age at delivery (years) 30.5 (5.8) 31.1 (5.8) 30.1 (6.6)
Maternal age at delivery ‡ 35 years 111 (20) 83 (27) 37 (24)
1-Hour oral glucose load screening test (mg/dL)* 171 (157–191) 162 (151–179) 174 (156–195)
3-Hour glucose load diagnostic test (mg/dL),
fasting (n = 1,004)
95 (85–107) 94 (84–106) 96 (86–109)
Medical management (vs. diet-control only)* 285 (52) 120 (39) 70 (45)
Any tobacco use reported in pregnancy* 3 (0.5) 54 (17) 20 (13)
Multiparity* 420 (76) 163 (52) 95 (61)
Chronic hypertension* 23 (4) 37 (12) 28 (18)
Multiple gestation 12 (2) 13 (12) 4 (3)
History of preeclampsia* 26 (5) 29 (9) 9 (6)
History of gestational diabetes 16 (3) 14 (5) 9 (6)
Placenta previa diagnosis 12 (2) 3 (1) 1 (1)
Induction of labor 208 (38) 114 (37) 59 (18)
Prior cesarean delivery 120 (22) 51 (16) 28 (18)
Breech presentation* 9 (2) 14 (5) 3 (2)
Placental abruption 6 (1) 4 (1) 2 (1)
Preterm premature rupture of membranes* 28 (5) 36 (12) 22 (14)
aNumbers may not add up to 100 because of rounding.
*p < 0.05.
SD, standard deviation; IQR, interquartile range; no, number.
524 BERGGREN ET AL.
Overall, Hispanic women were least likely to experience
one of our measured maternal or neonatal adverse outcomes.
Figure 2 shows the distribution of these outcomes. Half of all
Caucasian and African American women, compared with
44% of Hispanic women, had at least one maternal adverse
outcome ( p < 0.05). Similarly, half of all Caucasian and Afri-
can American women, compared with 41% of Hispanic wo-
men, had at least one adverse perinatal outcome ( p < 0.05).
Discussion
In a large retrospective cohort study of women in North
Carolina, GDM prevalence was approximately twice as
common among Hispanic women compared with Caucasian
and African American women. Hispanic women with GDM
were more likely to be prescribed medical therapy compared
with Caucasian women. Hispanic women were at lower risk
for preterm delivery, hypertensive disorders of pregnancy,
and NICU admission compared with Caucasian women but
were at greater risk of shoulder dystocia. In contrast to
Hispanic women, outcomes among African American wo-
men were similar to those of Caucasian women. Overall,
Hispanic women had fewer maternal and neonatal adverse
outcomes. The overall prevalence of at least one measured
adverse outcome, however, remained high in all racial/
ethnic groups.
Our findings differ from other studies measuring GDM
outcomes between Hispanic and non-Hispanic women.
Among an ethnically diverse California population of women
with GDM, Hispanic women were just as likely as Caucasian
women to require medical management of GDM and to de-
liver preterm at < 37 or < 34 weeks.15 Hispanic women in our
cohort were nearly half as likely to deliver a preterm infant at
< 37 or < 34 weeks or to deliver an LBW or VLBW, although
they were more likely to be prescribed medical management
of their GDM. Less preterm birth among Hispanic women
with GDM follows a phenomenon known as the Hispanic
Paradox, describing some better than expected health out-
comes in this racial/ethnic group.12 We report a nonstatistical
Table 3. Unadjusted and Adjusted Prevalence Ratios of Perinatal Outcomes Among Hispanics
and African Americans Compared to Reference Group, Caucasians
Hispanic vs. Caucasian African American vs. Caucasian
Perinatal outcomes PR (95% CI)a aPR (95% CI)a PR (95% CI) aPR (95% CI)
Medical management (vs. diet control only) 1.36 (1.15-1.60) 1.31 (1.10-1.56) 1.18 (0.94-1.48) 1.09 (0.87-1.37)
Macrosomia < 4,000 g 1.36 (0.95-1.96) 1.21 (0.83-1.76) 0.83 (0.47-1.46) 0.80 (0.42-1.37)
Low birth weight < 2,500 g 0.55 (0.37-0.82) 0.54 (0.36-0.82) 1.05 (0.66-1.67) 0.95 (0.60-1.51)
Very low birth weight < 1,500 g 0.19 (0.04-0.95) 0.20 (0.04-1.01) 2.34 (0.80-6.84) 2.05 (0.70-6.03)
Cesarean section (vs. spontaneous vaginal delivery) 0.91 (0.76-1.08) 0.88 (0.73-1.06) 1.08 (0.86-1.36) 1.07 (0.85-1.35)
Operative (vs. spontaneous vaginal delivery) 0.53 (0.32-0.88) 0.45 (0.27-0.77) 0.57 (0.26-1.25) 0.52 (0.24-1.15)
3rd or 4th degree perineal laceration 0.60 (0.30-1.20) 0.52 (0.26-1.04) 0.40 (0.12-1.37) 0.38 (0.11-1.34)
Preterm delivery < 37 weeks 0.58 (0.43-0.80) 0.58 (0.42-0.81) 1.00 (0.68-1.45) 0.92 (0.63-1.35)
Preterm delivery < 34 weeks 0.54 (0.29-0.99) 0.51 (0.27-0.96) 1.30 (0.67-2.55) 1.15 (0.59-2.27)
Preeclampsia 0.86 (0.52-1.42) 0.89 (0.51-1.54) 1.61 (0.91-2.88) 1.49 (0.82-2.70)
Gestational hypertension 0.39 (0.21-0.73) 0.43 (0.22-0.83) 0.86 (0.42-1.77) 0.91 (0.45-1.86)
Shoulder dystocia 3.13 (1.22-8.00) 3.52 (1.30-9.50) 2.76 (0.89-8.56) 2.46 (0.78-7.80)
NICU admission (n = 326) 0.73 (0.60-0.88) 0.72 (0.59-0.88) 0.83 (0.63-1.08) 0.80 (0.61-1.05)
> 24-hour NICU stay (if admitted) 0.83 (0.75-0.93) 0.81 (0.72-0.90) 1.01 (0.90-1.13) 1.00 (0.89-1.13)
aAll adjusted models include 1-hour oral glucose load results modeled as a continuous variable and any tobacco use in pregnancy as a
dichotomous variable.
aPR, adjusted prevalence rate; CI, confidence interval; PR, prevalence ratio.
FIG. 2. Adverse maternal and neonatal outcomes are more
common among Caucasian and African American women
than among Hispanic women ( p < 0.05): among maternal
outcomes, Caucasian 50% (95% CI 44%-56%), African
American 51% (95% CI 43%-59%), and Hispanic 44% (95% CI
40%-48%); among neonatal outcomes, Caucasian 51% (95%
CI 45%-57%), African American 49% (95% CI 39%-55%),
Hispanic 41% (95% CI 37%-45%).
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increased risk of macrosomia ( > 4,000 g) among Hispanic
women compared with Caucasian women, whereas other
studies found that Hispanic women were statistically more
likely to deliver an infant < 4,000 g.13, 14 As overall prevalence
of macrosomia was small in each retrospective analysis,
however, low power to detect true differences may explain
disparate findings.
Several strengths of our study exist. We examined a large,
clinically representative sample of all women delivered at our
institution who were diagnosed with GDM. Our 14-year da-
tabase of pregnancy diagnoses and pertinent adverse out-
comes avoids selection bias that exists when individuals are
recruited and enrolled in research studies. Further, using
GDM treatment data, we reported that Hispanic women in
our study were more likely to be prescribed medical treatment
compared with Caucasian women. These results suggest that
there are racial/ethnic differences in overall glycemic control.
These treatment differences may explain differences in peri-
natal outcomes compared with prior studies. Finally, differ-
ences in analytic approach may explain some differences in
our findings compared to findings in other work. We used
Poisson regression modeling and did not adjust for interme-
diates, such as gestational age at delivery, that might other-
wise have introduced bias.24
Our findings must be interpreted in the context of the ret-
rospective study design. Although GDM treatment with
glyburide or insulin was initiated and increased based on
established glucose thresholds in our prenatal clinic, we
cannot definitively report the percentage of women who
achieved adequate vs. poor glycemic control. Maternal height
and prepregnancy weight were not recorded in the UNC PD
throughout our study period. As we were unable to use these
variables, gestational weight gain, or BMI data in our analysis,
this may bias our findings, as obesity is associated with
pregnancy complications, including GDM, cesarean delivery,
and macrosomia.25
The observed associations between race/ethnicity and
perinatal outcomes may not reflect causal effects but rather
noncausal associations that arise in the subpopulation of
women with a diagnosis of GDM.26 As in any observational
study, we cannot determine causal associations. In addition,
measures of nativity or acculturation or proxies, such as lan-
guage preference, were not available in this cohort but have
been shown to impact perinatal outcomes9,27,28 and should be
included in future work examining ethnic differences in
health outcomes. Although our study cohort likely reflects the
demographics of Hispanic women in North Carolina, the
majority of whom are of Mexican origin, race/ethnicity still
describes a heterogeneous group. Caution should be used if
extrapolating our results by race/ethnicity to other Hispanic
groups.
Finally, we excluded women who were diagnosed based
on elevated 1-hour oral glucose load results or at provider
discretion and excluded women who did not undergo the
recommended 3-hour OGTT. If Hispanic women with more
severe glucose intolerance were more likely to be treated
presumptively or were more likely to not undergo the 3-hour
OGTT, this could have biased our results. However, Hispanic
women were actually least likely to be excluded and, among
our final sample, had the greatest prevalence of GDM. This
reduces our potential for bias. In fact, our data may under-
estimate the potential differences in perinatal outcomes, but
we a priori determined and maintained our analysis inclusion
criteria, including standard of care GDM screening and di-
agnostic tests.
Interestingly, Hispanic women had fewer measured ma-
ternal and neonatal adverse outcomes overall compared with
Caucasian and African American women, although not all
outcomes were less common. Hispanic women were more
likely to be prescribed medical treatment of GDM and were
less likely to have gestational hypertension, a diagnosis
known to improve with glycemic control. However, they
were more likely to have a shoulder dystocia at delivery, with
an infant birth weight approximately 150 g greater than that
of Caucasian infants born at similar gestational ages.
Although we know that strict glycemic control translates
to lower risk of GDM-associated adverse outcomes, perhaps
racial/ethnic differences exist in etiologies of hyperglyce-
mia in pregnancy. If, for instance, GDM among Hispanic
women is related to poor beta cell function, the need for
medical management to improve glycemic control is logical.
If inflammatory pathophysiology plays a greater role, how-
ever, among African American or Caucasian women com-
pared with Hispanic women, those two racial/ethnic groups
may be more responsive to diet control. Differences in risk of
hypertension by ethnicity have been demonstrated outside
of pregnancy, and underlying mechanisms are the focus of
ongoing research.11,29 Our data illustrate different needs in
GDM management and associated outcomes, but we do not
yet know how specific racial/ethnic groups would benefit
from tailored treatment. How we should adequately mea-
sure and achieve glycemic control to optimize perinatal
outcomes may differ by race/ethnicity. These plausible but
largely unstudied etiologies of racial/ethnic differences in
achieving glycemic control should be the focus of ongoing
and future research.
Conclusions
Our data demonstrate that racial/ethnic differences exist
among women with GDM, particularly when Hispanic wo-
men are compared with Caucasian women. These differences
may indicate a need for more aggressive treatment of GDM in
Hispanic women coupled with improved measures of gly-
cemic control. Hispanic groups are the largest and fastest
growing ethnic minority in the United States,18 and efforts
that improve perinatal outcomes among this group can have
further reaching positive public health implications. Further
studies are needed to determine the mechanisms underlying
our finding of lower rates of preterm birth and hypertensive
complications but higher rates of macrosomia-related out-
comes among Hispanic women.
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